NCT03023748View on ClinicalTrials.gov

Intravenous Paricalcitol in Chronic Hemodialysis Patients

PHASE4UnknownINTERVENTIONAL
Enrollment

30

Participants

Timeline

Start Date

September 30, 2011

Primary Completion Date

December 31, 2017

Study Completion Date

January 31, 2018

Conditions
Endstage Renal DiseaseSecondary Hyperparathyroidism
Interventions
DRUG

Intravenous Paricalcitol

Twenty four months of intravenous paricalcitol will be given twice or thrice weekly post-hemodialysis depending on frequency of hemodialysis of the patients

Trial Locations (1)

0000

Queen Mary Hospital and Tung Wah Hospital, Hong Kong

Sponsors

Collaborators (1)

AbbVie
All Listed Sponsors
collaborator

AbbVie

INDUSTRY

lead

The University of Hong Kong

OTHER